Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events.
Bilal A SiddiquiJinesh S GheeyaRohit GoswamyTharakeswara K BathalaDevaki Shilpa SurasiJianjun GaoAmishi ShahMatthew T CampbellPavlos MsaouelSangeeta GoswamiJennifer WangAmado J ZuritaEric JonaschPaul G CornAna M AparicioArlene O Siefker-RadtkePadmanee SharmaSumit K SubudhiNizar TannirPublished in: Journal for immunotherapy of cancer (2022)
ICT rechallenge after moderate-to-severe irAEs was associated with deep and durable responses in a subset of patients with RCC and UC, with acceptable safety and no fatal events. Strategies to enable ICT resumption after moderate-to-severe irAEs, such targeted immunosuppression, warrant further study.